On October 8, 2025, Relmada Therapeutics announced the appointment of Dr. Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to its Clinical Advisory Board. Dr. Kates will provide strategic guidance for the company’s lead oncology candidate, NDV‑01, a sustained‑release intravesical gemcitabine/docetaxel formulation for non‑muscle invasive bladder cancer. The appointment is part of Relmada’s plan to launch a Phase 3 program for NDV‑01 in the first half of 2026.
Dr. Kates brings extensive expertise to the advisory board, having chaired the landmark Phase 3 BRIDGE trial that compared gemcitabine/docetaxel to BCG in NMIBC. His experience in designing and conducting large‑scale urologic oncology studies positions him to help refine the Phase 3 protocol, optimize patient enrollment, and ensure real‑world applicability of NDV‑01’s administration. The board member’s background also signals to regulators and investors that Relmada is committed to leveraging top clinical expertise to accelerate development.
The addition of Dr. Kates is a strategic move that supports Relmada’s goal of advancing NDV‑01 toward regulatory approval and market entry. By strengthening the clinical advisory team, the company aims to reduce development risk, improve trial design, and potentially shorten the time to first‑in‑class approval. For investors, the appointment signals proactive steps toward achieving the next critical milestone, enhancing confidence in the company’s ability to progress its flagship oncology program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.